These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26002761)

  • 41. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis.
    Iftikhar IH; Alghothani L; Trotti LM
    Eur J Neurol; 2017 Dec; 24(12):1446-1456. PubMed ID: 28888061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transdermal rotigotine in restless legs syndrome: impulse control disorders.
    Prescrire Int; 2014 Oct; 23(153):239. PubMed ID: 25964969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Restless legs syndrome: clinical presentation diagnosis and treatment.
    Wijemanne S; Jankovic J
    Sleep Med; 2015 Jun; 16(6):678-90. PubMed ID: 25979181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
    Benes H
    Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
    Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R
    Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating restless legs syndrome with rotigotine.
    Reading P
    Br J Hosp Med (Lond); 2010 Apr; 71(4):216-9. PubMed ID: 20393432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daytime dysfunction in children with restless legs syndrome.
    Furudate N; Komada Y; Kobayashi M; Nakajima S; Inoue Y
    J Neurol Sci; 2014 Jan; 336(1-2):232-6. PubMed ID: 24360552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design.
    Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782
    [No Abstract]   [Full Text] [Related]  

  • 49. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.
    Allen RP; Ritchie SY
    Sleep Med; 2008 Dec; 9(8):899-902. PubMed ID: 18024167
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
    Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
    Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.
    Garcia-Borreguero D; Larrosa O; Williams AM; Albares J; Pascual M; Palacios JC; Fernandez C
    Neurology; 2010 Jun; 74(23):1897-904. PubMed ID: 20427750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome?
    Cuellar NG; Ratcliffe SJ
    Altern Ther Health Med; 2009; 15(2):22-8. PubMed ID: 19284179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Restless legs syndrome: clinical experience with long-term treatment.
    Clavadetscher SC; Gugger M; Bassetti CL
    Sleep Med; 2004 Sep; 5(5):495-500. PubMed ID: 15341896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment.
    Allen RP
    Int Rev Psychiatry; 2014 Apr; 26(2):248-62. PubMed ID: 24892899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The powerful pre-treatment effect: placebo responses in restless legs syndrome trials.
    de la Fuente-Fernández R
    Eur J Neurol; 2012 Oct; 19(10):1305-10. PubMed ID: 22537387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
    Stiasny K; Röbbecke J; Schüler P; Oertel WH
    Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.